Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

Abstract

More than half of colorectal tumors harbor activating mutations in RAS/RAF proteins. Selumetinib (AZD6244, ARRY-142886) is a small molecule kinase inhibitor targeting MEK kinase, downstream of RAS. We examined the efficacy and safety of selumetinib with irinotecan in second-line therapy. Patients with K-RAS mutated colorectal cancer, progressing on first… (More)
DOI: 10.1007/s00280-014-2625-3

Topics

Cite this paper

@article{Hochster2014ErratumTP, title={Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer}, author={Howard S. Hochster and Nataliya V Uboha and Wells A. Messersmith and Philip Jordan Gold and B. H. ONeil and D. Cohen and Chadrick E. Denlinger and S. Cohen and Cynthia Gail Leichman and Lawrence P Leichman and H Lenz}, journal={Cancer Chemotherapy and Pharmacology}, year={2014}, volume={75}, pages={17-23} }